Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Abbott Laboratories (Pakistan)'s EV-to-FCF or its related term are showing as below:
KAR:ABOT'
s EV-to-FCF Range Over the Past 10 Years
Min: -260.34 Med: 13.68 Max: 161.76
Current: 13.18
During the past 13 years, the highest EV-to-FCF of Abbott Laboratories (Pakistan) was 161.76. The lowest was -260.34. And the median was 13.68.
KAR:ABOT's EV-to-FCF is ranked better than 68.26% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs KAR:ABOT: 13.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbott Laboratories (Pakistan)'s PE Ratio (TTM) for today is calculated as:
Abbott Laboratories (Pakistan)'s share price for today is ₨926.63.
Abbott Laboratories (Pakistan)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨84.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Abbott Laboratories (Pakistan) EV-to-FCF Related Terms
Abbott Laboratories (Pakistan) EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories (Pakistan) EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories (Pakistan)'s EV-to-FCF falls into.
Abbott Laboratories (Pakistan)'s current Enterprise Value is ₨78,720 Mil.
Abbott Laboratories (Pakistan)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨6,249 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) (KAR:ABOT) has a EV-to-FCF of 12.60 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbott Laboratories (Pakistan) and its competitors. This is near median its historical median of 13.68. According to the industry distribution chart, Abbott Laboratories (Pakistan) ranks #179 out of 564 companies in the Drug Manufacturers industry, placing it in the top 31.7%.
Is Abbott Laboratories (Pakistan)'s EV-to-FCF too high?
Abbott Laboratories (Pakistan)'s current EV-to-FCF of 12.60 is near median its 10-year median of 13.68. The Drug Manufacturers industry median EV-to-FCF is 20.90. Abbott Laboratories (Pakistan)'s value of 12.60 is 39.7% below this industry median. Based on the distribution chart, Abbott Laboratories (Pakistan) ranks #179 out of 564 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott Laboratories (Pakistan) ranks #179 out of 564 companies for EV-to-FCF. This puts Abbott Laboratories (Pakistan) in the upper half of its industry. The industry median EV-to-FCF is 20.90. Abbott Laboratories (Pakistan)'s value of 12.60 is 39.7% below this benchmark. While the company's 10-year median is 13.68 vs. the industry median of 20.90, Abbott Laboratories (Pakistan) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories (Pakistan)'s current EV-to-FCF of 12.60 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbott Laboratories (Pakistan) and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories (Pakistan)'s current EV-to-FCF is 12.60, which is near median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,008.89, compared to a current price of ₨926.63 — trading 8.2% below its estimated fair value. The current EV-to-FCF is 12.60, which is near median its 10-year median of 13.68 and 39.7% below the Drug Manufacturers industry median of 20.90. Abbott Laboratories (Pakistan)'s overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current EV-to-FCF is 12.60 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨926.63 is trading 8.2% below its estimated GF Value™ of ₨1,008.89.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
EV-to-FCF: 12.60 (near median its 10-year median of 13.68)
GF Value™: ₨1,008.89 vs. price of ₨926.63 (8.2% below fair value)
Industry Position: 39.7% below the Drug Manufacturers median (#179 of 564)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
76GF Score
Get the complete analysis for KAR:ABOT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
